Roggwil, November 10th, 2020 – Sales of the tinnitus therapy device tinniwell have multiplied in 2020 compared to last year. The 3rd series was delivered last month and due to the high demand, production of the 4th series has now started. The reason for this development is, on the one hand, the high rate of re-recommendations of healed former patients, as well as the complete digitalization of sales. In order to meet the growing challenges, the company migrated to a new CRM system (customer relationship management). With the Salesforce solution from the US, the increased requirements of sales as well as the requirements of the medical device regulation according to MDR can now be mapped.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016. Resaphene Deutschland GmbH in Constance, Resaphene UK Ltd. act as further sales companies in London and Resaphene US LLC in the US.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
T. +41 714500668